Physician profile
Ossama Labib
NPI 1225033673
$11,511.48
in general payments reported to CMS, 2019-2025
47 companies · $1,143 in 2025
The $1,143 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,185 · 2020: $1,406 · 2021: $2,319 · 2022: $1,875 · 2023: $1,942 · 2024: $1,641 · 2025: $1,143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,706 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,706.31 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,035.72 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $1,351.68 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $1,006.17 | 2019-2025 | |
| Abbvie INC. | $998.04 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $554.94 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Teva Pharmaceuticals USA, INC. | $540.72 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Janssen Pharmaceuticals, INC | $433.96 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $421.12 | 2019-2025 | Ozempic, Rybelsus |
| Nestle Healthcare Nutrition INC. | $393.12 | 2020-2023 | |
| Amgen INC. | $383.97 | 2019-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $351.99 | 2021-2023 | |
| Mylan Specialty L.P. | $338.01 | 2019-2024 | Yupelri |
| Lilly USA, LLC | $301.03 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Phathom Pharmaceuticals, INC. | $208.50 | 2023-2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $201.69 | 2019-2024 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ossama Labib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.